BRPI0409787B8 - antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a - Google Patents

antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a

Info

Publication number: BRPI0409787B8
Authority: BR; Brazil
Prior art keywords: triazol; pyrazol; alkynyl; alkenyl; receptor antagonists
Prior art date: 2003-04-23

Application number

Other languages

English (en)

Inventor

Stamford Andrew

R Neustadt Bernard

D Boyle Craig

Liu Hong

Hao Jinsong

Chackalamannil Samuel

G Shah Unmesh

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-23

Filing date

2004-04-21

Publication date

2021-05-25

2004-04-21 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2006-05-30 Publication of BRPI0409787A publication Critical patent/BRPI0409787A/pt

2018-08-21 Publication of BRPI0409787B1 publication Critical patent/BRPI0409787B1/pt

2021-05-25 Publication of BRPI0409787B8 publication Critical patent/BRPI0409787B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI0409787-4 2003-04-23 2004-04-21 antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a BRPI0409787B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46484003P	2003-04-23	2003-04-23
US60/464,840		2003-04-23
PCT/US2004/012471 WO2004094431A2 (en)	2003-04-23	2004-04-21	2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists

Publications (3)

Publication Number	Publication Date
BRPI0409787A BRPI0409787A (pt)	2006-05-30
BRPI0409787B1 BRPI0409787B1 (pt)	2018-08-21
BRPI0409787B8 true BRPI0409787B8 (pt)	2021-05-25

Family

ID=33310963

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0409787-4 BRPI0409787B8 (pt)	2003-04-23	2004-04-21	antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a

Country Status (31)

Country	Link
US (2)	US6897217B2 (pt)
EP (1)	EP1622912B1 (pt)
JP (2)	JP4527712B2 (pt)
KR (1)	KR100831107B1 (pt)
CN (1)	CN100503609C (pt)
AR (1)	AR044041A1 (pt)
AT (1)	ATE432282T1 (pt)
AU (1)	AU2004233334B2 (pt)
BR (1)	BRPI0409787B8 (pt)
CA (1)	CA2522813C (pt)
CL (1)	CL2004000847A1 (pt)
CO (1)	CO5700766A2 (pt)
CY (1)	CY1109263T1 (pt)
DE (1)	DE602004021250D1 (pt)
DK (1)	DK1622912T3 (pt)
EC (1)	ECSP056115A (pt)
ES (1)	ES2326270T3 (pt)
HR (1)	HRP20090394T1 (pt)
IL (1)	IL171567A (pt)
MX (1)	MXPA05011366A (pt)
MY (1)	MY139344A (pt)
NO (1)	NO332182B1 (pt)
NZ (1)	NZ542823A (pt)
PE (1)	PE20050141A1 (pt)
PL (2)	PL378867A1 (pt)
PT (1)	PT1622912E (pt)
RU (1)	RU2373210C2 (pt)
SI (1)	SI1622912T1 (pt)
TW (2)	TWI355381B (pt)
WO (1)	WO2004094431A2 (pt)
ZA (1)	ZA200508489B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7313588B1 (en) *	2000-07-13	2007-12-25	Biap Systems, Inc.	Locally executing software agent for retrieving remote content and method for creation and use of the agent
US6916811B2 (en) *	2001-11-30	2005-07-12	Schering Corporation	Adenosine A2a receptor antagonists
US20060128694A1 (en) *	2002-12-19	2006-06-15	Michael Grzelak	Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
TWI331036B (en)	2002-12-19	2010-10-01	Schering Corp	Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
AU2004233334B2 (en) *	2003-04-23	2010-08-12	Merck Sharp & Dohme Corp.	2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
EP1745047B1 (en) *	2004-04-21	2010-03-24	Schering Corporation	Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
EP2258372B8 (en) *	2005-06-07	2012-12-19	Kyowa Hakko Kirin Co., Ltd.	A2A antagonists for use in the treatment of motor disorders
CA2622741A1 (en)	2005-09-19	2007-03-29	Schering Corporation	2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
AR056080A1 (es)	2005-09-23	2007-09-19	Schering Corp	7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es)	2005-10-14	2008-06-01	Universidad De Barcelona	Compuestos para el tratamiento de la fibrilacion auricular.
US7723343B2 (en) *	2007-03-30	2010-05-25	King Pharmaceuticals Research And Development, Inc.	Adenosine A2A receptor antagonists
WO2009111449A1 (en) *	2008-03-04	2009-09-11	Schering Corporation	1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
US8512594B2 (en) *	2008-08-25	2013-08-20	Air Products And Chemicals, Inc.	Curing agent of N,N′-dimethyl-meta-xylylenediamine and multifunctional amin(s)
US8501997B2 (en) *	2008-08-25	2013-08-06	Air Products And Chemicals, Inc.	Curing agent for low temperature cure applications
US8288390B2 (en)	2009-03-10	2012-10-16	Takeda Pharmaceutical Company Limited	Benzofuran derivatives
WO2011017299A2 (en)	2009-08-07	2011-02-10	Schering Corporation	PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
US8420661B2 (en) *	2010-04-13	2013-04-16	Hoffmann-La Roche Inc.	Arylethynyl derivatives
EP2797879B1 (en) *	2011-12-27	2018-12-26	Bio-Pharm Solutions Co., Ltd.	Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
WO2014101120A1 (en)	2012-12-28	2014-07-03	Merck Sharp & Dohme Corp.	Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
DK3269716T3 (da) *	2013-03-14	2020-10-19	Galapagos Nv	Hidtil ukendte forbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske lidelser
EP3723754A4 (en)	2017-12-13	2021-05-19	Merck Sharp & Dohme Corp.	IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
EP3999513A4 (en) *	2019-07-17	2022-12-21	Teon Therapeutics, Inc.	ADENOSIN A2A RECEPTOR ANTAGONISTS AND USES THEREOF
CN115160120B (zh) *	2022-08-02	2024-08-27	乐威医药（江苏）股份有限公司	一种多烷氧基芳香酮的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US785906A (en) *	1904-12-06	1905-03-28	Albert P Mcbride	Casing packer and shoe for gas or oil wells.
MX16165A (es) *	1988-05-25	1994-02-28	Dow Chemical Co	Alcoxi-1,2,4-triazolo[1,5-c]pirimidin-2-sulfonamidas, procedimiento para su preparacion e intermediarios.
IT1264901B1 (it)	1993-06-29	1996-10-17	Schering Plough S P A	Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ES2165393T3 (es)	1993-07-27	2002-03-16	Kyowa Hakko Kogyo Kk	Remedio contra la enfermedad de parkinson.
IT1277392B1 (it)	1995-07-28	1997-11-10	Schering Plough S P A	Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it)	1997-05-21	1999-01-07	Schering Plough S P A	Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
DE19826843A1 (de) *	1998-06-16	1999-12-23	Boehringer Ingelheim Pharma	Neue Imidazotriazolopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MY132006A (en) *	2000-05-26	2007-09-28	Schering Corp	ADENOSINE A2a RECEPTOR ANTAGONISTS
GB0100624D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VII
KR20030076633A (ko) *	2001-02-05	2003-09-26	가부시키 가이샤 오오쯔카 세이야쿠 고우죠우	트리아조로퀴나졸린 및 피라졸로 트리아조로피리미딘유도체, 의약조성물,아데노신 에이3 수용체 친화제,안압저하제, 녹내장의 예방 및 치료를 위한 제제 및안압저하 방법
HUP0401777A3 (en)	2001-10-15	2008-06-30	Schering Corp	3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds
TWI331036B (en) *	2002-12-19	2010-10-01	Schering Corp	Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
AU2004233334B2 (en) *	2003-04-23	2010-08-12	Merck Sharp & Dohme Corp.	2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

2004
- 2004-04-21 AU AU2004233334A patent/AU2004233334B2/en not_active Ceased
- 2004-04-21 PL PL378867A patent/PL378867A1/pl unknown
- 2004-04-21 MX MXPA05011366A patent/MXPA05011366A/es active IP Right Grant
- 2004-04-21 HR HR20090394T patent/HRP20090394T1/xx unknown
- 2004-04-21 CN CNB2004800107535A patent/CN100503609C/zh not_active Expired - Fee Related
- 2004-04-21 TW TW093111142A patent/TWI355381B/zh not_active IP Right Cessation
- 2004-04-21 AR ARP040101344A patent/AR044041A1/es not_active Application Discontinuation
- 2004-04-21 DK DK04760128T patent/DK1622912T3/da active
- 2004-04-21 CL CL200400847A patent/CL2004000847A1/es unknown
- 2004-04-21 ES ES04760128T patent/ES2326270T3/es not_active Expired - Lifetime
- 2004-04-21 CA CA002522813A patent/CA2522813C/en not_active Expired - Fee Related
- 2004-04-21 KR KR1020057019891A patent/KR100831107B1/ko not_active Expired - Fee Related
- 2004-04-21 RU RU2005136166/04A patent/RU2373210C2/ru not_active IP Right Cessation
- 2004-04-21 PL PL04760128T patent/PL1622912T3/pl unknown
- 2004-04-21 SI SI200431189T patent/SI1622912T1/sl unknown
- 2004-04-21 PT PT04760128T patent/PT1622912E/pt unknown
- 2004-04-21 BR BRPI0409787-4 patent/BRPI0409787B8/pt not_active IP Right Cessation
- 2004-04-21 MY MYPI20041463A patent/MY139344A/en unknown
- 2004-04-21 PE PE2004000392A patent/PE20050141A1/es not_active Application Discontinuation
- 2004-04-21 EP EP04760128A patent/EP1622912B1/en not_active Expired - Lifetime
- 2004-04-21 TW TW100131963A patent/TWI375677B/zh not_active IP Right Cessation
- 2004-04-21 AT AT04760128T patent/ATE432282T1/de active
- 2004-04-21 NZ NZ542823A patent/NZ542823A/en not_active IP Right Cessation
- 2004-04-21 WO PCT/US2004/012471 patent/WO2004094431A2/en not_active Ceased
- 2004-04-21 DE DE602004021250T patent/DE602004021250D1/de not_active Expired - Lifetime
- 2004-04-21 US US10/829,416 patent/US6897217B2/en not_active Expired - Lifetime
- 2004-04-21 JP JP2006501291A patent/JP4527712B2/ja not_active Expired - Fee Related
2005
- 2005-05-23 US US11/135,261 patent/US7368449B2/en not_active Expired - Lifetime
- 2005-10-19 ZA ZA200508489A patent/ZA200508489B/en unknown
- 2005-10-21 CO CO05107374A patent/CO5700766A2/es active IP Right Grant
- 2005-10-21 EC EC2005006115A patent/ECSP056115A/es unknown
- 2005-10-26 IL IL171567A patent/IL171567A/en active IP Right Grant
- 2005-11-22 NO NO20055510A patent/NO332182B1/no not_active IP Right Cessation
2009
- 2009-08-04 CY CY20091100821T patent/CY1109263T1/el unknown
- 2009-11-04 JP JP2009253549A patent/JP2010059178A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
PL378867A1 (pl)	2006-05-29
CA2522813A1 (en)	2004-11-04
DK1622912T3 (da)	2009-09-07
ES2326270T3 (es)	2009-10-06
US20050222164A1 (en)	2005-10-06
DE602004021250D1 (de)	2009-07-09
NZ542823A (en)	2009-03-31
CN1777609A (zh)	2006-05-24
TWI375677B (en)	2012-11-01
BRPI0409787A (pt)	2006-05-30
ECSP056115A (es)	2006-03-01
ATE432282T1 (de)	2009-06-15
AU2004233334A1 (en)	2004-11-04
US6897217B2 (en)	2005-05-24
PT1622912E (pt)	2009-08-17
RU2005136166A (ru)	2006-06-10
TW201144317A (en)	2011-12-16
HRP20090394T1 (hr)	2009-08-31
CY1109263T1 (el)	2014-07-02
BRPI0409787B1 (pt)	2018-08-21
JP4527712B2 (ja)	2010-08-18
KR100831107B1 (ko)	2008-05-20
US20040220194A1 (en)	2004-11-04
EP1622912A2 (en)	2006-02-08
KR20060005379A (ko)	2006-01-17
PL1622912T3 (pl)	2009-11-30
NO20055510D0 (no)	2005-11-22
TWI355381B (en)	2012-01-01
SI1622912T1 (sl)	2009-10-31
IL171567A (en)	2013-01-31
WO2004094431A3 (en)	2004-12-02
WO2004094431A2 (en)	2004-11-04
NO332182B1 (no)	2012-07-23
JP2010059178A (ja)	2010-03-18
HK1085466A1 (en)	2006-08-25
RU2373210C2 (ru)	2009-11-20
PE20050141A1 (es)	2005-04-01
AU2004233334B2 (en)	2010-08-12
CN100503609C (zh)	2009-06-24
CA2522813C (en)	2009-09-08
MXPA05011366A (es)	2005-11-28
NO20055510L (no)	2006-01-20
JP2006523619A (ja)	2006-10-19
EP1622912B1 (en)	2009-05-27
CL2004000847A1 (es)	2005-03-11
AR044041A1 (es)	2005-08-24
ZA200508489B (en)	2007-04-25
MY139344A (en)	2009-09-30
TW200427689A (en)	2004-12-16
CO5700766A2 (es)	2006-11-30
US7368449B2 (en)	2008-05-06

Publication	Publication Date	Title
BRPI0409787B8 (pt)	2021-05-25	antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a
IL178674A0 (en)	2007-02-11	PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS
IL160878A0 (en)	2004-08-31	Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists
ATE317844T1 (de)	2006-03-15	Adenosine a2a receptor antagonisten
DE60110219D1 (de)	2005-05-25	Adenosin a2a rezeptor antagonisten
DE60234951D1 (de)	2010-02-11	Adenosin a2a rezeptor antagonisten
TWI365879B (en)	2012-06-11	A2b adenosine receptor antagonists
DE60219196D1 (de)	2007-05-10	BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
IL178365A (en)	2010-12-30	Selective antagonists of a2a adenosine receptors
SMP200600024B (it)	2006-07-19	2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
DK1608654T3 (da)	2010-04-26	8-substituerede-6, 7, 8, 9-tetrahydropyrimido (1,2- a) pyrimidin-4-on-derivater
NO20054331D0 (no)	2005-09-20	Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
DK1678182T3 (da)	2007-06-04	Fremgangsmåde til fremstilling af substituerede 5-amino-pyrazolo[4,3-E]-1,2,4-triazolo-[1,5-C]pyrimidiner
ATE338043T1 (de)	2006-09-15	5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
EP1636230A4 (en)	2010-06-16	ADENOSINE A1 RECEPTOR ANTAGONISTS
HK1118045A (en)	2009-01-30	2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
TH0401001406A (th)	2016-05-19	2-อัลไคนิล-และ 2-อัลคีนิล-ไพราโซโล-[4,3-e]-1,2,4-ไตรอะโซโล-[1,5-c]-ไพริมิดีน ที่เป็นแอนทาโกนิสท์ของตัวรับอะดีโนซีนA2a
ZA200608778B (en)	2008-09-25	Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
HK1062534A (en)	2004-11-12	Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists
PL378983A1 (pl)	2006-06-26	Pochodne ksantyny jako antagoniści receptora adenozyny A2B
HK1099015A (en)	2007-08-03	Selective antagonists of a2a adenosine receptors
PL383615A1 (pl)	2008-04-14	Arylindenopirydyny i arylindenopirymidyny oraz ich zastosowanie jako antagonistów receptora adenozynowego A2a

Legal Events

Date	Code	Title	Description
2011-03-09	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2013-09-17	B25D	Requested change of name of applicant approved	Owner name: MERCK SHARP AND DOHME CORP. (US)
2013-10-15	B25G	Requested change of headquarter approved	Owner name: MERCK SHARP AND DOHME CORP. (US)
2015-09-22	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-20	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2018-05-02	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2018-07-24	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2018-08-21	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2023-02-14	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 19A ANUIDADE.
2023-05-30	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2719 DE 14-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.